70.67 USD
▼-10.00-12.40%
盘后 72.00 +1.88%
2026-09-15
市值
$9.98B
市盈率
—
EPS
-2.28
股息率
—
52 周区间
28.12 – 95.49
成交量
4.37M
Beta
1.28
目标价
110.00
52W 低 28.1252W 高 95.49
价格走势
公司简介
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...